United Therapeutics Corp. (NASDAQ:UTHR)’s share price fell 2.4% during trading on Thursday . The stock traded as low as $111.93 and last traded at $112.09, with a volume of 327,114 shares trading hands. The stock had previously closed at $114.83.

Several brokerages have recently commented on UTHR. Argus lowered United Therapeutics Corp. from a “buy” rating to a “hold” rating and set a $114.00 price target on the stock. in a research note on Tuesday, May 24th. Zacks Investment Research lowered United Therapeutics Corp. from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 8th. Cowen and Company reaffirmed a “buy” rating on shares of United Therapeutics Corp. in a research note on Sunday, April 17th. Ladenburg Thalmann lowered United Therapeutics Corp. from a “buy” rating to a “neutral” rating in a research note on Friday, April 29th. Finally, HC Wainwright lowered United Therapeutics Corp. from a “buy” rating to a “neutral” rating and decreased their price target for the company from $175.00 to $95.00 in a research note on Wednesday, June 15th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $138.00.

The company has a market cap of $4.97 billion and a P/E ratio of 6.37. The firm has a 50 day moving average of $108.88 and a 200 day moving average of $117.72.

United Therapeutics Corp. (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, April 28th. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.21 by $0.19. During the same period last year, the firm earned $2.55 earnings per share. The business earned $369 million during the quarter, compared to the consensus estimate of $395.02 million. The business’s quarterly revenue was up 12.7% compared to the same quarter last year. Analysts expect that United Therapeutics Corp. will post $14.17 earnings per share for the current year.

In other news, CEO Martine A. Rothblatt sold 5,546 shares of the firm’s stock in a transaction on Thursday, May 5th. The stock was sold at an average price of $107.79, for a total transaction of $597,803.34. Following the sale, the chief executive officer now owns 5,786 shares in the company, valued at $623,672.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,284 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $112.77, for a total value of $144,796.68. Following the sale, the chief executive officer now owns 1,424 shares in the company, valued at approximately $160,584.48. The disclosure for this sale can be found here.

Several large investors have bought and sold shares of UTHR. State of Tennessee Treasury Department boosted its stake in United Therapeutics Corp. by 29.9% in the fourth quarter. State of Tennessee Treasury Department now owns 86,900 shares of the biotechnology company’s stock valued at $13,609,000 after buying an additional 20,000 shares during the period. TrimTabs Asset Management LLC boosted its stake in United Therapeutics Corp. by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 13,856 shares of the biotechnology company’s stock valued at $2,170,000 after buying an additional 258 shares during the period. Dimensional Fund Advisors LP boosted its stake in United Therapeutics Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 138,293 shares of the biotechnology company’s stock valued at $21,660,000 after buying an additional 4,251 shares during the period. Matarin Capital Management LLC acquired a new stake in United Therapeutics Corp. during the fourth quarter valued at about $4,154,000. Finally, Globeflex Capital L P acquired a new stake in United Therapeutics Corp. during the fourth quarter valued at about $2,061,000.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.